Clopidogrel Tablet, Film Coated
Product Images NDC 68788-4173

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68788-4173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel Tab Usp 75mg (Clopidogrel 75mg 30s Count Cntr Label)

Label for Clopidogrel Tab. USP, 75 mg film-coated tablets. The label includes the manufacturer MSN Laboratories Pvt. Ltd and mentions the product is generic for Plavix. It provides storage instructions, a caution about federal law prohibiting transfer, and a barcode. The label also includes directions in English and a Spanish instruction section highlighted in yellow, along with placeholders for lot, batch, expiration date, and NDC information.*

FDA Label Image

Figure-1 (Clopidogrel Figure 1)

A chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel. The chart shows mean and 90% confidence intervals relative to clopidogrel administered alone, comparing dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg.*

FDA Label Image

Figure-2 (Clopidogrel Figure 2)

A cumulative event rate line graph showing cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare Clopidogrel (+ aspirin) and placebo (+ aspirin), with Clopidogrel showing a lower cumulative event rate. The graph includes a statistical significance value (P=0.00009).*

FDA Label Image

Figure-3-cont (Clopidogrel Figure 3 Cont)

A forest plot chart presenting hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups including Heparin/LMWH use, Aspirin dosage, CYPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. The graph visually indicates whether outcomes favor Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot displaying hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, and overall population. The x-axis represents hazard ratios ranging approximately from 0.3 to 1.4, showing subgroup-specific treatment effects favoring Clopidogrel or placebo.*

FDA Label Image

Figure-4 (Clopidogrel Figure 4)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge between placebo and clopidogrel groups over 28 days since randomization. The y-axis shows the percentage dead, and the x-axis shows days since randomization (up to 28). Data indicates 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the clopidogrel group, with a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure-5 (Clopidogrel Figure 5)

A line graph comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days between placebo and Clopidogrel groups. The y-axis shows the percentage with events, and the x-axis shows days since randomization. The graph indicates a 9% proportional risk reduction for Clopidogrel versus placebo.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart showing odds ratios with 99% confidence intervals comparing Clopidogrel versus placebo across various subgroups. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart visualizes favorability towards Clopidogrel or placebo for each subgroup with corresponding numerical data for Clopidogrel and placebo counts and percentages.*

FDA Label Image

Figure-7 (Clopidogrel Figure 7)

A line graph titled 'Fatal or Nonfatal Vascular Events' showing cumulative event rate (%) on the y-axis and months of follow-up on the x-axis. Two lines represent event rates for Aspirin and Clopidogrel over a 36-month period, with Clopidogrel's line slightly lower than Aspirin's. The graph includes a P-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot chart displays hazard ratios with 95% confidence intervals comparing Clopidogrel and Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The x-axis shows hazard ratios from 0.6 to 1.3, with markers indicating favor towards Clopidogrel or Aspirin for each condition.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure diagram of clopidogrel bisulfate, showing its molecular components including a thiophene ring, methoxy group, and chloride-substituted aromatic ring with sulfate ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.